Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Feb 2025
Cheaper medicine for lung cancer patients
2 February 2025 - The Australian Government is listing Retevmo (selpercatinib) on the PBS for the first time to treat advanced ...
Posted by Michael Wonder on 02 Feb 2025
US FDA approves Celltrion's Avtozma (tocilizumab-anoh), a biosimilar to Actemra
30 January 2025 - Approval was received for multiple indications, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic ...
Posted by Michael Wonder on 02 Feb 2025
Cell and gene therapies - improving access and outcomes for Medicare and Medicaid beneficiaries
1 February 2025 - State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements ...
Posted by Michael Wonder on 01 Feb 2025
High quality evidence for the treatment of very rare diseases: IQWiG is involved in the EU project RealiseD
29 January 2025 - Developing clinical studies for good evidence on very rare diseases in order to arrive at effective therapies ...
Posted by Michael Wonder on 01 Feb 2025
The use of real world data for estimating relative treatment effects in NICE health technology assessment submissions: a review
1 February 2025 - This paper investigates the current use of real world data for estimating relative treatment effects in NICE ...
Posted by Michael Wonder on 01 Feb 2025
Groundbreaking one-off gene therapy approved for severe sickle cell disease
31 January 2025 - People in England with severe sickle cell disease will be among the first to receive treatment using ...
Posted by Michael Wonder on 01 Feb 2025
Bupa and Healthscope end battle over hospital payments, meaning no gap fees for stays
31 January 2025 - Millions of Bupa customers will avoid incurring gap fees for stays at Healthscope hospitals after the ...
Posted by Michael Wonder on 01 Feb 2025
Schedule of Pharmaceutical Benefits - 1 February 2025
1 February 2025 - The February 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Feb 2025
New Zealand Pharmaceutical Schedule - 1 February 2025
1 February 2025 - The February 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Feb 2025
FDA approves novel non-opioid treatment for moderate to severe acute pain
30 January 2025 - First drug approved in new class of non-pioid pain medicines; agency continues to take steps to support ...
Posted by Michael Wonder on 01 Feb 2025
Refined interpretation of the Mutual Recognition Agreement between Canada and Switzerland
31 January 2025 - Swissmedic and Health Canada agreed to expand their approach regarding the implementation of the current mutual ...
Posted by Michael Wonder on 01 Feb 2025
Boehringer Ingelheim’s Jardiance gets expanded coverage for HFpEF patients
31 January 2025 - Boehringer Ingelheim Korea said that Jardiance (empagliflozin) 10 mg tablet, its sodium-glucose co-transporter-2 inhibitor, received expanded ...
Posted by Michael Wonder on 01 Feb 2025
PHARMAC reconsiders oestradiol patch options following community feedback
29 January 2025 - PHARMAC is reviewing and reconsidering its oestradiol patch options after considerable feedback was received when it ...
Posted by Michael Wonder on 31 Jan 2025
Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR positive, HER2 negative breast cancer
31 January 2025 - Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease ...
Posted by Michael Wonder on 31 Jan 2025
Bristol Myers Squibb receives positive CHMP opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma
31 January 2025 - Recommendation based on results of Phase 3 CheckMate-9DW clinical trial demonstrating statistically significant and clinically meaningful ...